News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
485,763 Results
Type
Article (8016)
Company Profile (140)
Press Release (477606)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166739)
Career Advice (304)
Deals (25738)
Drug Delivery (7)
Drug Development (52873)
Employer Resources (14)
FDA (9760)
Job Trends (8572)
News (238192)
Policy (17898)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (488)
Accelerated approval (26)
ADA (18)
Adcomms (1)
Allergies (97)
Alliances (33154)
ALS (107)
Alzheimer's disease (984)
Antibody-drug conjugate (ADC) (279)
Approvals (10398)
Artificial intelligence (327)
ASCO (159)
Autoimmune disease (218)
Automation (29)
Bankruptcy (263)
Belgium (1)
Best Places to Work (6958)
BIO (37)
Biologics (9)
BIOSECURE Act (1)
Biosimilars (115)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (139)
Brain cancer (30)
Breast cancer (516)
Cancer (3732)
Cardiovascular disease (225)
Career advice (245)
Career pathing (1)
CAR-T (177)
CDMO (12)
Celiac Disease (1)
Cell therapy (483)
Cervical cancer (35)
Clinical research (48001)
Collaboration (1270)
Commercialization (3)
Compensation (1523)
Complete response letters (34)
COVID-19 (758)
CRISPR (64)
C-suite (794)
Cystic fibrosis (86)
Data (5819)
Denatured (4)
Depression (103)
Dermatology (67)
Diabetes (351)
Diagnostics (4202)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (158)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (166)
Earnings (73743)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (88061)
Executive appointments (710)
FDA (12459)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (24)
Funding (937)
Gene editing (126)
Generative AI (9)
Gene therapy (329)
GLP-1 (294)
Government (946)
Grass and pollen (2)
Guidances (281)
Healthcare (9367)
Hematology (94)
HIV (53)
Huntington's disease (22)
IgA nephropathy (66)
Immunology and inflammation (101)
Immuno-oncology (61)
Indications (159)
Infectious disease (948)
Inflammatory bowel disease (128)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (259)
Interviews (41)
IPO (12387)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5195)
Licensing (17)
Liver cancer (45)
Longevity (19)
Lung cancer (529)
Lymphoma (257)
Machine learning (27)
Management (3)
Manufacturing (558)
Marketing (8)
MASH (118)
Medical affairs (2)
Medical device (8676)
Medtech (8831)
Mergers & acquisitions (14404)
Metabolic disorders (722)
mRNA (60)
Multiple sclerosis (107)
NASH (4)
Neurodegenerative disease (224)
Neuropsychiatric disorders (40)
Neuroscience (1855)
NextGen: Class of 2026 (3150)
Non-profit (843)
Obesity (230)
Opinion (10)
Ovarian cancer (161)
Pain (177)
Pancreatic cancer (205)
Parkinson's disease (204)
Partnered (12)
Patents (491)
Patient recruitment (526)
Patient selection (1)
Peanut (31)
People (41331)
Peptides (1)
Pharmaceutical (30)
Pharmacy benefit managers (9)
Phase 1 (15507)
Phase 2 (21431)
Phase 3 (14453)
Pipeline (7626)
Policy (18)
Postmarket research (1570)
Preclinical (6550)
Press Release (34)
Prostate cancer (193)
Psychedelics (7)
Radiopharmaceuticals (194)
Rare diseases (585)
Real estate (3022)
Recruiting (6)
Regulatory (14916)
Reports (23)
Research institute (584)
Resumes & cover letters (45)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (102)
Series A (158)
Series B (122)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (90)
Sponsored (5)
Startups (2020)
Stomach cancer (3)
Supply chain (51)
Vaccines (332)
Venture capital (17)
Weight loss (74)
Women's health (85)
Date
Today (61)
Last 7 days (408)
Last 30 days (1324)
Last 365 days (19072)
2026 (13400)
2025 (19252)
2024 (22986)
2023 (26538)
2022 (34592)
2021 (37176)
2020 (33469)
2019 (23275)
2018 (17468)
2017 (18765)
2016 (17917)
2015 (24263)
2014 (21679)
2013 (18135)
2012 (20222)
2011 (20440)
2010 (20332)
Location
Africa (228)
Alabama (76)
Alaska (2)
Arizona (309)
Arkansas (11)
Asia (17946)
Australia (2106)
California (12286)
Canada (3219)
China (541)
Colorado (491)
Connecticut (424)
Delaware (211)
Europe (24684)
Florida (1844)
Georgia (392)
Hawaii (3)
Idaho (46)
Illinois (722)
India (52)
Indiana (321)
Iowa (16)
Japan (418)
Kansas (102)
Kentucky (31)
Louisiana (27)
Maine (26)
Maryland (1227)
Massachusetts (8065)
Michigan (312)
Minnesota (568)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (119)
New Hampshire (60)
New Jersey (2681)
New Mexico (12)
New York (2881)
North Carolina (1312)
North Dakota (4)
Northern California (6174)
Ohio (290)
Oklahoma (14)
Oregon (16)
Pennsylvania (2290)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (77)
South Dakota (1)
Southern California (5113)
Tennessee (123)
Texas (1991)
United States (39830)
Utah (367)
Vermont (1)
Virginia (158)
Washington D.C. (38)
Washington State (955)
West Virginia (1)
Wisconsin (74)
Wyoming (1)
485,763 Results for "eirgenix inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
EirGenix Showcases Dual-Track Biosimilars and CDMO Strategy in U.S. Market Push at BIO 2026
June 30, 2026
·
6 min read
Press Releases
EirGenix Signed The Commercial Licensing Agreement for Its Second HER2 Biosimilar Asset EG1206A
November 13, 2025
·
3 min read
Press Releases
EirGenix Signed The Commercial Licensinse Agreement for It’s Second HER2 Biosimilar Asset EG1206A
November 12, 2025
·
3 min read
EirGenix’s Breast Cancer Biosimilar Receives Marketing Authorization by EC
EirGenix Inc. announced that its trastuzumab biosimilar medicine which their commercial partner Sandoz plans to commercialise had received a marketing authorization from the European Commission.
November 22, 2023
·
2 min read
Press Releases
Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers
August 28, 2026
·
3 min read
Drug Development
EirGenix’s Second Breast Cancer Biosimilar EG1206A Successfully Reaches Phase 1 Clinical Trial Objectives
EirGenix, Inc. (6589.TT) announced on 28th of April that it has completed the phase 1 clinical trial (EGC101) of its second breast cancer biosimilar EG1206A in Europe.
May 2, 2023
·
3 min read
Press Releases
Transcenta Therapeutics Announces Strategic Collaboration and Non-exclusive Licensing Agreement to Advance Integrated Continuous Biomanufacturing and Expand Global Access to Affordable Biologics
December 29, 2025
·
3 min read
Eirgenix Receives Approval from Japan’s PMDA
EirGenix’s World-Class Biopharmaceutical Manufacturing Facility Becomes the First of Its Kind in Taiwan to Receive Approval
February 14, 2020
·
3 min read
Drug Development
Positive Phase III Clinical Results for EirGenix’s Proposed Trastuzumab Biosimilar
In a press conference today, EirGenix, Inc. (6589.TT) announced that the Phase III clinical trial (Trial No.: EGC002, NCT03433313) of its breast cancer biosimilar, EG12014 (proposed trastuzumab biosimilar, also called EGI014), has met its primary endpoint. EG12014 has shown equivalent efficacy to Herceptin® in regards to its clinical response
March 24, 2021
·
4 min read
Business
EirGenix’s cancer therapeutic drug EG12014 (Trastuzumab biosimilar) is approved for phase III clinical trial
EirGenix is a biologics development and contract development & manufacturing organization. EirGenix Inc. has formed a strategic alliance with Formosa Laboratories Inc. to provide contract development & manufacturing services of antibody drug conjugates (ADC).
February 8, 2019
·
1 min read
1 of 48,577
Next
